Kura Oncology Inc at Stifel Targeted Oncology Days (Virtual) Transcript
Thanks, everyone, for continuing to join us for the fireside chat sessions for the Stifel Inaugural Target Oncology Days that I'm hosting with my colleague analysts, Ben Burnett and Steve Willey. Happy to continue this fireside with Kura for this session. Got Troy Wilson, President and CEO, who needs little introduction. So thanks for joining us, Troy.
Questions & Answers
And maybe just -- we'll jump right in if you can help us orient the discussion that we're going to have around ziftomenib, your menin inhibitor by discussing some of the ASH '22 data and the priced EHA '23 abstracts that was released -- a degree of efficacy relative to competitors and other targeted therapies. And then really with the abstract focus on the NPM1, what are the key elements that were updated there?
Sure, Brad. Let me start by thanking you and Stifel for having this opportunity to chat
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |